Published in Mol Ther on January 31, 2012
Development of Gene Transfer for Induction of Antigen-specific Tolerance. Mol Ther Methods Clin Dev (2014) 0.93
Center for fetal monkey gene transfer for heart, lung, and blood diseases: an NHLBI resource for the gene therapy community. Hum Gene Ther (2012) 0.88
Hematopoietic stem cell gene therapy:assessing the relevance of preclinical models. Semin Hematol (2013) 0.86
The road to purified hematopoietic stem cell transplants is paved with antibodies. Curr Opin Immunol (2012) 0.80
Targeted approaches to induce immune tolerance for Pompe disease therapy. Mol Ther Methods Clin Dev (2016) 0.77
Cell cycle status of CD34(+) hemopoietic stem cells determines lentiviral integration in actively transcribed and development-related genes. Mol Ther (2014) 0.77
Optimizing drug therapy in pediatric SCT: focus on pharmacokinetics. Bone Marrow Transplant (2014) 0.76
Limiting Thymic Precursor Supply Increases the Risk of Lymphoid Malignancy in Murine X-Linked Severe Combined Immunodeficiency. Mol Ther Nucleic Acids (2016) 0.75
Prediction of Intravenous Busulfan Clearance by Endogenous Plasma Biomarkers Using Global Pharmacometabolomics. Metabolomics (2016) 0.75
A formula to estimate the approximate surface area if height and weight be known. 1916. Nutrition (1992) 16.89
Gene therapy for immunodeficiency due to adenosine deaminase deficiency. N Engl J Med (2009) 8.20
Correction of ADA-SCID by stem cell gene therapy combined with nonmyeloablative conditioning. Science (2002) 6.46
Sustained correction of X-linked severe combined immunodeficiency by ex vivo gene therapy. N Engl J Med (2002) 6.25
Gene therapy of X-linked severe combined immunodeficiency by use of a pseudotyped gammaretroviral vector. Lancet (2004) 5.43
T-cell mediated rejection of gene-modified HIV-specific cytotoxic T lymphocytes in HIV-infected patients. Nat Med (1996) 3.88
Efficacy of gene therapy for X-linked severe combined immunodeficiency. N Engl J Med (2010) 3.54
Gene therapy in peripheral blood lymphocytes and bone marrow for ADA- immunodeficient patients. Science (1995) 2.79
Immune response to green fluorescent protein: implications for gene therapy. Gene Ther (1999) 2.27
Engraftment of gene-modified umbilical cord blood cells in neonates with adenosine deaminase deficiency. Nat Med (1995) 2.15
Efficient gene transfer into rhesus repopulating hematopoietic stem cells using a simian immunodeficiency virus-based lentiviral vector system. Blood (2004) 1.99
Induction of cytotoxic T-lymphocyte responses to enhanced green and yellow fluorescent proteins after myeloablative conditioning. Blood (2003) 1.61
Prolonged production of NADPH oxidase-corrected granulocytes after gene therapy of chronic granulomatous disease. Proc Natl Acad Sci U S A (1997) 1.48
Efficient transduction of pigtailed macaque hematopoietic repopulating cells with HIV-based lentiviral vectors. Blood (2008) 1.37
Nonmyeloablative immunosuppressive regimen prolongs In vivo persistence of gene-modified autologous T cells in a nonhuman primate model. J Virol (2001) 1.34
Nonmyeloablative conditioning is sufficient to allow engraftment of EGFP-expressing bone marrow and subsequent acceptance of EGFP-transgenic skin grafts in mice. Blood (2003) 1.33
Lentivirus vector-mediated hematopoietic stem cell gene transfer of common gamma-chain cytokine receptor in rhesus macaques. J Virol (2001) 1.30
Immune response to fetal calf serum by two adenosine deaminase-deficient patients after T cell gene therapy. Hum Gene Ther (2002) 1.27
Prolonged high-level detection of retrovirally marked hematopoietic cells in nonhuman primates after transduction of CD34+ progenitors using clinically feasible methods. Mol Ther (2000) 1.26
Removal of T cells from bone marrow for transplantation. Comparison of rat monoclonal anti-lymphocyte antibodies of different isotypes. Mol Biol Med (1983) 1.21
Intrapulmonary and intramyocardial gene transfer in rhesus monkeys (Macaca mulatta): safety and efficiency of HIV-1-derived lentiviral vectors for fetal gene delivery. Mol Ther (2005) 1.14
The enhanced green fluorescent protein (eGFP) is minimally immunogenic in C57BL/6 mice. Gene Ther (2001) 1.11
High fludarabine exposure and relationship with treatment-related mortality after nonmyeloablative hematopoietic cell transplantation. Bone Marrow Transplant (2010) 1.09
F-ara-A pharmacokinetics during reduced-intensity conditioning therapy with fludarabine and busulfan. Bone Marrow Transplant (2007) 1.00
Transplantation of human peripheral blood stem cells into fetal rhesus monkeys (Macaca mulatta). Transplantation (2000) 0.97
Effects of busulfan dose escalation on engraftment of infant rhesus monkey hematopoietic stem cells after gene marking by a lentiviral vector. Exp Hematol (2006) 0.97
Effect of age on the frequency, cell cycle, and lineage maturation of rhesus monkey (Macaca mulatta) CD34+ and hematopoietic progenitor cells. Pediatr Res (2005) 0.92
Phase I clinical trials with fludarabine phosphate. Semin Oncol (1990) 0.90
Fludarabine phosphate: A DNA synthesis inhibitor with potent immunosuppressive activity and minimal clinical toxicity. Am Surg (1996) 0.86
Phase I clinical investigation of 9-beta-D-arabinofuranosyl-2-fluoroadenine 5'-monophosphate (NSC 312887), a new purine antimetabolite. Cancer Res (1984) 0.86
In vivo marking of rhesus monkey lymphocytes by adeno-associated viral vectors: direct comparison with retroviral vectors. Blood (1999) 0.85
High levels of lymphoid expression of enhanced green fluorescent protein in nonhuman primates transplanted with cytokine-mobilized peripheral blood CD34(+) cells. Blood (2000) 0.85
Pharmacology of fludarabine phosphate after a phase I/II trial by a loading bolus and continuous infusion in pediatric patients. Cancer Res (1990) 0.82
Lentiviral vectors with amplified beta cell-specific gene expression. Gene Ther (2009) 0.80
Human hematopoietic stem/progenitor cells modified by zinc-finger nucleases targeted to CCR5 control HIV-1 in vivo. Nat Biotechnol (2010) 6.55
Salivary transcriptome diagnostics for oral cancer detection. Clin Cancer Res (2004) 4.15
Salivary microRNA: discovery, characterization, and clinical utility for oral cancer detection. Clin Cancer Res (2009) 3.86
Impact of obesity on biochemical control after radical prostatectomy for clinically localized prostate cancer: a report by the Shared Equal Access Regional Cancer Hospital database study group. J Clin Oncol (2003) 3.62
Genome characteristics of facultatively symbiotic Frankia sp. strains reflect host range and host plant biogeography. Genome Res (2006) 3.53
Propionibacterium acnes strain populations in the human skin microbiome associated with acne. J Invest Dermatol (2013) 3.32
Salivary proteomic and genomic biomarkers for primary Sjögren's syndrome. Arthritis Rheum (2007) 2.90
Salivary proteomics for oral cancer biomarker discovery. Clin Cancer Res (2008) 2.81
Green tea polyphenols block the anticancer effects of bortezomib and other boronic acid-based proteasome inhibitors. Blood (2009) 2.61
Redirecting specificity of T-cell populations for CD19 using the Sleeping Beauty system. Cancer Res (2008) 2.57
Genetic therapies against HIV. Nat Biotechnol (2007) 2.50
CD4+CD25bright regulatory T cells actively regulate inflammation in the joints of patients with the remitting form of juvenile idiopathic arthritis. J Immunol (2004) 2.45
Variations of oral microbiota are associated with pancreatic diseases including pancreatic cancer. Gut (2011) 2.38
Prognostic impact of micrometastases in colon cancer: interim results of a prospective multicenter trial. Ann Surg (2007) 2.28
β-cell mass and turnover in humans: effects of obesity and aging. Diabetes Care (2012) 2.20
Salivary transcriptomic biomarkers for detection of resectable pancreatic cancer. Gastroenterology (2009) 2.13
Growth inhibitory effect of low fat diet on prostate cancer cells: results of a prospective, randomized dietary intervention trial in men with prostate cancer. J Urol (2010) 1.94
Transient gene expression by nonintegrating lentiviral vectors. Mol Ther (2006) 1.89
Gene therapy for adenosine deaminase-deficient severe combined immune deficiency: clinical comparison of retroviral vectors and treatment plans. Blood (2012) 1.85
Transplantation outcomes for severe combined immunodeficiency, 2000-2009. N Engl J Med (2014) 1.81
Long-term luciferase expression monitored by bioluminescence imaging after adeno-associated virus-mediated fetal gene delivery in rhesus monkeys (Macaca mulatta). Hum Gene Ther (2010) 1.80
Dynamic tracking of human hematopoietic stem cell engraftment using in vivo bioluminescence imaging. Blood (2003) 1.79
Lung cancer chemoprevention with celecoxib in former smokers. Cancer Prev Res (Phila) (2011) 1.77
FOXC1 is a potential prognostic biomarker with functional significance in basal-like breast cancer. Cancer Res (2010) 1.73
Myeloid suppressor cell depletion augments antitumor activity in lung cancer. PLoS One (2012) 1.70
Marrow-derived cells as vehicles for delivery of gene therapy to pulmonary epithelium. Am J Respir Cell Mol Biol (2002) 1.70
Serum circulating human mRNA profiling and its utility for oral cancer detection. J Clin Oncol (2006) 1.67
Genome sequence and analysis of the soil cellulolytic actinomycete Thermobifida fusca YX. J Bacteriol (2007) 1.67
Electrochemical sensor for multiplex biomarkers detection. Clin Cancer Res (2009) 1.67
The prognostic effect of micrometastases in previously staged lymph node negative (N0) colorectal carcinoma: a meta-analysis. Ann Surg Oncol (2006) 1.66
Newborn screening for severe combined immunodeficiency and T-cell lymphopenia in California: results of the first 2 years. J Allergy Clin Immunol (2013) 1.66
Clonality analysis after retroviral-mediated gene transfer to CD34+ cells from the cord blood of ADA-deficient SCID neonates. Nat Med (2003) 1.65
Should a positive surgical margin following radical prostatectomy be pathological stage T2 or T3? Results from the SEARCH database. J Urol (2003) 1.63
Epitope-specific immunotherapy induces immune deviation of proinflammatory T cells in rheumatoid arthritis. Proc Natl Acad Sci U S A (2004) 1.62
Antitumor activity from antigen-specific CD8 T cells generated in vivo from genetically engineered human hematopoietic stem cells. Proc Natl Acad Sci U S A (2011) 1.61
Reduction of the efficacy of methotrexate by the use of folic acid: post hoc analysis from two randomized controlled studies. Arthritis Rheum (2005) 1.61
Quantitative F18-fluorodeoxyglucose positron emission tomography accurately characterizes peripheral nerve sheath tumors as malignant or benign. Cancer (2010) 1.56
Gene therapy for rare diseases: summary of a National Institutes of Health workshop, September 13, 2012. Hum Gene Ther (2013) 1.54
Expansion of multipotent and lymphoid-committed human progenitors through intracellular dimerization of Mpl. Blood (2008) 1.51
Prognostic significance of molecular upstaging of paraffin-embedded sentinel lymph nodes in melanoma patients. J Clin Oncol (2004) 1.50
Effect of altering dietary omega-6/omega-3 fatty acid ratios on prostate cancer membrane composition, cyclooxygenase-2, and prostaglandin E2. Clin Cancer Res (2006) 1.50
Randomized clinical trial of brewed green and black tea in men with prostate cancer prior to prostatectomy. Prostate (2014) 1.47
FDG-PET/CT imaging predicts histopathologic treatment responses after the initial cycle of neoadjuvant chemotherapy in high-grade soft-tissue sarcomas. Clin Cancer Res (2009) 1.47
Green and black tea consumption and risk of stroke: a meta-analysis. Stroke (2009) 1.46
Renal ontogeny in the rhesus monkey (Macaca mulatta) and directed differentiation of human embryonic stem cells towards kidney precursors. Differentiation (2009) 1.45
Discovery and preclinical validation of salivary transcriptomic and proteomic biomarkers for the non-invasive detection of breast cancer. PLoS One (2010) 1.43
A modified γ-retrovirus vector for X-linked severe combined immunodeficiency. N Engl J Med (2014) 1.42
Calcium-activated endoplasmic reticulum stress as a major component of tumor cell death induced by 2,5-dimethyl-celecoxib, a non-coxib analogue of celecoxib. Mol Cancer Ther (2007) 1.41
Long-term efficacy of enzyme replacement therapy for adenosine deaminase (ADA)-deficient severe combined immunodeficiency (SCID). Clin Immunol (2005) 1.40
The natural history of children with severe combined immunodeficiency: baseline features of the first fifty patients of the primary immune deficiency treatment consortium prospective study 6901. J Clin Immunol (2013) 1.40
The genome sequence of the psychrophilic archaeon, Methanococcoides burtonii: the role of genome evolution in cold adaptation. ISME J (2009) 1.40
Clinical efficacy of gene-modified stem cells in adenosine deaminase-deficient immunodeficiency. J Clin Invest (2017) 1.39
Exon-level expression profiling: a comprehensive transcriptome analysis of oral fluids. Clin Chem (2008) 1.38
Adipocytes impair leukemia treatment in mice. Cancer Res (2009) 1.38
Cyclooxygenase-2-dependent activation of signal transducer and activator of transcription 3 by interleukin-6 in non-small cell lung cancer. Clin Cancer Res (2005) 1.37
Prostate cancer originating in basal cells progresses to adenocarcinoma propagated by luminal-like cells. Proc Natl Acad Sci U S A (2013) 1.37
Role of pancreatic cancer-derived exosomes in salivary biomarker development. J Biol Chem (2013) 1.37
The dual EGFR/HER2 inhibitor lapatinib synergistically enhances the antitumor activity of the histone deacetylase inhibitor panobinostat in colorectal cancer models. Cancer Res (2011) 1.34
Factors influencing the titer and infectivity of lentiviral vectors. Hum Gene Ther (2004) 1.32
Abnormal function of high-density lipoprotein is associated with poor disease control and an altered protein cargo in rheumatoid arthritis. Arthritis Rheum (2009) 1.31
Identification of common predictive markers of in vitro response to the Mek inhibitor selumetinib (AZD6244; ARRY-142886) in human breast cancer and non-small cell lung cancer cell lines. Mol Cancer Ther (2010) 1.30
American Society of Gene Therapy (ASGT) ad hoc subcommittee on retroviral-mediated gene transfer to hematopoietic stem cells. Mol Ther (2003) 1.29
Selective survival of peripheral blood lymphocytes in children with HIV-1 following delivery of an anti-HIV gene to bone marrow CD34(+) cells. Mol Ther (2005) 1.28
Tumor response to combination celecoxib and erlotinib therapy in non-small cell lung cancer is associated with a low baseline matrix metalloproteinase-9 and a decline in serum-soluble E-cadherin. J Thorac Oncol (2008) 1.28
Allogeneic hematopoietic cell transplantation for primary immune deficiency diseases: current status and critical needs. J Allergy Clin Immunol (2008) 1.25
Neonatal gene therapy of MPS I mice by intravenous injection of a lentiviral vector. Mol Ther (2005) 1.25
Profiling cancer gene mutations in clinical formalin-fixed, paraffin-embedded colorectal tumor specimens using targeted next-generation sequencing. Oncologist (2014) 1.24
Gene therapy fulfilling its promise. N Engl J Med (2009) 1.24
Phase II prospective randomized trial of a low-fat diet with fish oil supplementation in men undergoing radical prostatectomy. Cancer Prev Res (Phila) (2011) 1.23
Improving cellular therapy for primary immune deficiency diseases: recognition, diagnosis, and management. J Allergy Clin Immunol (2009) 1.23
β-globin gene transfer to human bone marrow for sickle cell disease. J Clin Invest (2013) 1.22
Effects of ApoE4 and maternal history of dementia on hippocampal atrophy. Neurobiol Aging (2010) 1.22
Predicting treatment outcomes and responder subsets in scleroderma-related interstitial lung disease. Arthritis Rheum (2011) 1.22
Preclinical validation of salivary biomarkers for primary Sjögren's syndrome. Arthritis Care Res (Hoboken) (2010) 1.21
Proteomic profiling following immunoaffinity capture of high-density lipoprotein: association of acute-phase proteins and complement factors with proinflammatory high-density lipoprotein in rheumatoid arthritis. Arthritis Rheum (2012) 1.20
Hepatitis B virus promotes hepatocarcinogenesis in transgenic mice. Hepatology (2007) 1.19
Effects of pharmacists' interventions on patient outcomes in an HIV primary care clinic. Am J Health Syst Pharm (2007) 1.19
High mobility group A2 potentiates genotoxic stress in part through the modulation of basal and DNA damage-dependent phosphatidylinositol 3-kinase-related protein kinase activation. Cancer Res (2005) 1.18
WNT10B/β-catenin signalling induces HMGA2 and proliferation in metastatic triple-negative breast cancer. EMBO Mol Med (2013) 1.17
The Moloney murine leukemia virus repressor binding site represses expression in murine and human hematopoietic stem cells. J Virol (2003) 1.17
CpeR is an activator required for expression of the phycoerythrin operon (cpeBA) in the cyanobacterium Fremyella diplosiphon and is encoded in the phycoerythrin linker-polypeptide operon (cpeCDESTR). Mol Microbiol (2002) 1.16
Effect of low-fat diet on development of prostate cancer and Akt phosphorylation in the Hi-Myc transgenic mouse model. Cancer Res (2008) 1.16
The CXCR2 antagonist, SCH-527123, shows antitumor activity and sensitizes cells to oxaliplatin in preclinical colon cancer models. Mol Cancer Ther (2012) 1.15
Treatment of the mouse model of mucopolysaccharidosis I with retrovirally transduced bone marrow. Mol Genet Metab (2003) 1.15
Aggravated endoplasmic reticulum stress as a basis for enhanced glioblastoma cell killing by bortezomib in combination with celecoxib or its non-coxib analogue, 2,5-dimethyl-celecoxib. Cancer Res (2008) 1.15
Celecoxib analogs that lack COX-2 inhibitory function: preclinical development of novel anticancer drugs. Expert Opin Investig Drugs (2008) 1.15
Systems biology analysis of Sjögren's syndrome and mucosa-associated lymphoid tissue lymphoma in parotid glands. Arthritis Rheum (2009) 1.14
Generation and characterization of transgene-free human induced pluripotent stem cells and conversion to putative clinical-grade status. Stem Cell Res Ther (2013) 1.14
Gene expression profile of metastatic colon cancer cells resistant to cisplatin-induced apoptosis. Int J Oncol (2003) 1.14
Gene therapy/bone marrow transplantation in ADA-deficient mice: roles of enzyme-replacement therapy and cytoreduction. Blood (2012) 1.14
In vivo biosafety model to assess the risk of adverse events from retroviral and lentiviral vectors. Mol Ther (2008) 1.14
Intrapulmonary and intramyocardial gene transfer in rhesus monkeys (Macaca mulatta): safety and efficiency of HIV-1-derived lentiviral vectors for fetal gene delivery. Mol Ther (2005) 1.14
Advances in lentiviral vector design for gene-modification of hematopoietic stem cells. Curr Opin Biotechnol (2002) 1.13
Stable gene transfer to human CD34(+) hematopoietic cells using the Sleeping Beauty transposon. Exp Hematol (2006) 1.13
IL-7 promotes CXCR3 ligand-dependent T cell antitumor reactivity in lung cancer. J Immunol (2009) 1.12
A metaproteomic approach to study human-microbial ecosystems at the mucosal luminal interface. PLoS One (2011) 1.12